Neuroendocrinology

Original Paper

Inhibition by Melatonin of Dopamine Release from Rat Hypothalamus in vitro: Variations with Sex and the Estrous Cycle

Zisapel N. · Egozi Y. · Laudon M.

Author affiliations

Department of Biochemistry, George S. Wise Faculty of Life Sciences, Tel-Aviv University, Tel-Aviv, Israel

Related Articles for ""

Neuroendocrinology 1983;37:41–47

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 25, 1982
Accepted: February 14, 1983
Published online: March 27, 2008
Issue release date: 1983

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Abstract

The inhibitory effect of melatonin on evoked dopamine release from whole hypothalamus as well as from its three regions (preoptic area, median and posterior hypothalamus) was studied in male rats and in female rats during various stages of the estrous cycle. Inhibition of dopamine release by 1 μM melatonin was significantly higher at the estrous and lower at the diestrous than at the metestrous and proestrous stages. The variations in inhibition of dopamine release during the estrous cycle occurred predominantly in the preoptic area, and were nonsignificant in the other hypothalamic regions. In male rats, a constant level of inhibition was observed. In addition, the concentration of melatonin needed to produce half maximal effect in the female shifted from approximately 0.6 nM at the estrous and metestrous stages to more than 1 μM at the proestrous and diestrous stages. The corresponding concentration in male rats was of the order of 1 μM, and did not change.

© 1983 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: October 25, 1982
Accepted: February 14, 1983
Published online: March 27, 2008
Issue release date: 1983

Number of Print Pages: 7
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP